Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

(2011) Philippe Metellus et al.   JOURNAL OF NEURO-ONCOLOGY

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma

(2009) Alba A. Brandes et al.   CANCER

Analysis ofIDH1andIDH2mutations in Japanese glioma patients

(2009) Yukihiko Sonoda et al.   CANCER SCIENCE

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study

(2008) Izabela Zawlik et al.   NEUROEPIDEMIOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY